CABALETTA BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.69 USD | +13.00% |
|
+5.05% | -44.10% |
| Mar. 22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
| Mar. 21 | Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the Cabaletta Bio...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
12.69
USD
Average target price
34
USD
Spread / Average Target
+167.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.10% | 612M | |
| +7.52% | 113B | |
| +11.38% | 106B | |
| -12.64% | 22.22B | |
| +0.44% | 22.27B | |
| -4.18% | 19.43B | |
| -37.85% | 17.87B | |
| -8.58% | 17.24B | |
| +37.41% | 12.52B | |
| -23.95% | 8.34B |
- Stock Market
- Equities
- CABA Stock
- News Cabaletta Bio, Inc.
- Transcript : Cabaletta Bio, Inc. - Special Call
